136562-77-1

Basic information

• Product Name: 3-oxo-3-(4-phenoxyphenyl)propanenitrile
• Synonyms: 3-oxo-3-(4-phenoxyphenyl)propanenitrile
• CAS NO: 136562-77-1
• Molecular Weight: 237.258
• Mol File: 136562-77-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-oxo-3-(4-phenoxyphenyl)propanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxo-3-(4-phenoxyphenyl)propanenitrile(136562-77-1)
• EPA Substance Registry System: 3-oxo-3-(4-phenoxyphenyl)propanenitrile(136562-77-1)

Safety Data

• Hazardous Substances Data: 136562-77-1(Hazardous Substances Data)

Upstream product

• 2215-78-3 (4-phenoxyphenyl)methanol 
• 75-05-8 acetonitrile 
• 51067-38-0 4-phenoxyphenylboronic acid 
• 109-77-3 malononitrile 
• 2215-77-2 4-Phenoxybenzoic acid 
• 883560-03-0 2-cyano-3-oxo-3-(4-phenoxy-phenyl)-propionic acid methyl ester 
• 13075-63-3 2-chloro-1-(4-(phenoxy)phenyl)ethanone 

Downstream Products

• 883560-04-1 2-(4-phenoxy-phenyl)-pyrazolo[1,5-a]pyrimidine-6-carbonitrile 
• 501902-74-5 5-(4-phenoxy-phenyl)-1H-pyrazol-3-ylamine 

Relevant articles and documents

Selective Synthesis of β-Ketonitriles via Catalytic Carbopalladation of Dinitriles

A practical, convenient, and highly selective method of synthesizing β-ketonitriles from the Pd-catalyzed addition of organoboron reagents to dinitriles has been developed. This method provides excellent functional-group tolerance, a broad scope of substrates, and the convenience of using commercially available substrates. The method is expected to show further utility in future synthetic procedures.

Methods for Chk2 inhibitor patient selection

The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids, such as silencing interference RNA's specific for a Chk2 expression. Other Chk2 inhibitors may comprises proteins, such as antibodies. For example, the present invention contemplates that when a Chk2 inhibitor is administered during, or after, ionizing radiation tumor cell apoptosis is increased.